In July 2025, the Company entered into a securities purchase agreement with Mast Hill Fund LP ("Mast Hill"), under which the Company issued one convertible note in the aggregate principal amount of $…
In consideration for the Merger, on May 1, 2026 Lunai issued to the Holders an aggregate of eight (8) shares of a newly designated series of preferred stock of the Company, designated as “Series B Co…
The Series B Preferred Stock was allocated five (5) shares to the Company (representing 62.5% of the Series B Preferred Stock and an aggregate Stated Value of $12,500,000) and three (3) shares to Pel…
The Agreement establishes a framework for the joint development, and manufacturing of AI-enabled, GMP-compliant robotic systems for use in pharmaceutical and related manufacturing environments. The i…
In connection with the formation of the JV, the Company contributed license rights OT-101 for both U.S. and the rest of the world, in exchange for a 45% equity interest in GMP Biotechnology Limited (…
Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, …
The Company has agreed to issue to Autotelic, Inc. a number of shares of Common Stock equal to ten percent (10%) of the fully diluted outstanding shares of Oncotelic Therapeutics, Inc.
Reciprocal relationship from PPCB graph: novel expression system and are also in the process of optimizing conditions to achieve high titers of recombinant trypsinogen and chymotrypsinogen. Further, …
Oncotelic Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
OTLC-DEBT-11618
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
OTLC-DEBT-11617
Warrants outstanding: 10576924
90%
xbrl warrant detail from xbrl 2024-09-30.
Oncotelic Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Oncotelic Therapeutics, Inc..
Oncotelic Therapeutics, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Oncotelic Therapeutics, Inc..
Oncotelic Therapeutics, Inc. Extended Supply Chain Network
